Clinical Trial Update: BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers [Phase 2]

View source ↗

Summary

This clinical trial update indicates that the Phase 2 study of BKM120 (buparlisib) in advanced, metastatic, or recurrent endometrial cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• BKM120 (Buparlisib)

Snippet

Sponsor: University of Utah | Conditions: Endometrial Cancer | Phase 2 | Status: WITHDRAWN